CTRI/2025/10/096435Not yet recruitingNot Applicable
An open-label, balanced, randomized, single-dose, four treatment, single period, parallel oral bioavailability study comparing the test product of BioMK7 CWD 1 mg capsule and BioMK7 CWS 1 mg capsule by Morel Bio Science Private Limited with that of reference product of Vita MK7 1 mg capsule by Gnosis lesaffre and Menaquine Gold 1 mg capsule by Viridis Biopharma in healthy, adult human participants under fasting conditions.
Morel Bio Science Private Limited1 site in 1 country44 target enrollmentStarted: November 5, 2025Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 44
- Locations
- 1
- Primary Endpoint
- To demonstrate the oral bioavailability in healthy adult human subjects under fasting conditions.
Study Overview
Brief Summary
This study is a Nutraceutical study. The title of study is An open-label, balanced, randomized, single-dose, four treatment, single period, parallel, oral bioavailability study comparing the test products BioMK7 CWD 1 mg capsule and BioMK7 CWS 1 mg capsule by Morel Bio Science Private Limited with that of reference products Vita MK7 1 mg capsule by Gnosis lesaffre and Menquine Gold 1 mg capsule by Viridis Biopharma in healthy, adult human participants under fasting conditions. The primary objective of the study is to demonstrate oral bioavailability of the investigational products and the secondary objective of the study is To monitor the safety and tolerability of the test product in healthy, adult, human participants. A total of 44 healthy, adult, human participants shall be enrolled in the study. The total duration of the study will be at least 11 days. A total of 29 pre-dose and post-dose blood samples will be collected in single period for the study to meet primary objective.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- None
Eligibility Criteria
- Ages
- 18.00 Year(s) to 45.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Healthy, non-smoking, non-alcoholic, adult, human volunteer (Male and/or non-pregnant, non-lactating female) aged between 18 to 45 years (inclusive of both).
- •Volunteer with a BMI between 18.5 kg/m2 and 30.0 kg/m2 (inclusive of both) and weight at least 50 kgs for male subjects and 45 kgs for female volunteers.
- •Healthy according to the laboratory results and physical examination, performed within 28 days prior to the commencement of the dosing.
- •Participant having normal 12-lead electrocardiogram (ECG).
- •Participant having normal chest X- Ray (P/A view).
- •A negative urine screen result for drugs of abuse.
- •Participant able to communicate effectively.
- •Participant willing to adhere to protocol requirements as evidenced by written informed consent approved by an IEC/IRB.
- •Participants willing to give written informed consent and adhere to all the requirements of this protocol.
- •Ability to fast for at least 10.00 hours prior to dosing, 04.00 hours post-dose.
- •Male participant agreeing to use appropriate contraceptive measures like double barrier method (condom + diaphragm, condom or diaphragm + spermicidal gel or foam) and should not donate sperm during the study and for 07 days following last dose of the study medication.
- •If study participant is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence: Or Is postmenopausal for at least 1 year.
- •Or Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the study subject).
Exclusion Criteria
- •Known hypersensitivity to Menaquinone-7 (MK-7), or any of the excipients in the formulation.
- •History or presence of any medical condition or disease according to the opinion of the physician.
- •Volunteers with metabolic or gastrointestinal diseases, chronic degenerative or inflammatory diseases, anaemia, pregnancy, diabetes mellitus, soy allergy, abuse of drugs/alcohol, use of corticosteroids, oral anticoagulants, salicylates, antibiotics, use of vitamin K supplements and high dietary intake of vitamin K.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •Difficulty with donating blood or difficulty in accessibility of veins.
- •Difficulty in swallowing capsules.
- •An unusual or abnormal diet within 48.00 hours prior to study check-in, for whatever reason e.g., because of fasting due to religious reasons.
- •Participants who had planned surgery during the course of the trial.
- •History or current diagnosis of any cancer.
- •History or presence of significant alcoholism or drug abuse.
- •History of smoking.
- •History of gall bladder issues.
- •Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.
- •Pulse rate less than 60 beats/minute or more than 100 beats/minute.
- •Respiratory rate less than 14 breaths per minute or more than 18 breaths per minute.
- •Any significant/abnormal values of laboratory tests.
- •Major illness during 90 days before screening.
- •Use of any prescribed medication or OTC medication during last two weeks or 5 half-life of that particular drug whichever is higher before dosing and unwilling to follow throughout the study.
- •Use of any medications or dietary supplements of Vitamin K during last two weeks.
- •Consumed caffeine and /or xanthine-containing foods or beverages (i.e., coffee, tea, and caffeine-containing sodas, colas, etc.), grapefruit juice and poppy containing foods for at least 48.00 hours prior to initiation of the study and unwilling to follow throughout the study.
- •Participation in a drug research study within past 90 days.
- •Donation of blood in the past 90 days prior to study check-in.
- •In case of female volunteers, Pregnant or lactating Women.
Outcomes
Primary Outcomes
To demonstrate the oral bioavailability in healthy adult human subjects under fasting conditions.
Time Frame: Baseline Pre-dose blood samples will be collected at Day-2 and Day -1, Day 1 and the post-dose samples will be collected on Days 1,2,3,4,5,6 and 8 at 01.00, 02.00, 03.00, 04.00, 05.00, 05.50, 06.00, 06.50, 07.00, 07.50, 08.00, 09.00, 10.00, 12.00, 14.00, 16.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 and 168.00 hours.
Secondary Outcomes
- To monitor the safety and tolerability of the test product in healthy, adult, human participants.(Vital signs and well-being will be evaluated at the time of screening, check-in and at -48.00, -24.00, 00.00 before dosing and 02.00, 04.00, 06.00, 09.00, 24.00, 36.00, 48.00, and 60.00 hours after dosing and at the time of check-out.)
Investigators
Dr C Amulya
Noah Therapeutics Private Limited
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
An Open Label Study Single Dose Crossover Oral Bioequivalence Study Comparing Dexamfetamine Sulfate 5 mg TabletsCTRI/2024/11/077313Nova Pharmaceuticals Australasia Pty Ltd24
Completed
Phase 4
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagliflozin tablets 10mg, manufactured by Sun Pharmaceutical Industries Limited, India with Forxiga (Dapagliflozin) film-coated tablets 10 mg, manufactured by AstraZeneca AB Gärtunavägen, SE-151 85 Södertälje Sweden, in healthy adult, human subjects under fasting conditiondiabetes2023-506408-18-00Sun Pharmaceutical Industries Limited48
Completed
Phase 4
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.2023-507991-32-00Sun Pharmaceutical Industries Limited32
Completed
Phase 4
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaftor film coated tablets 150 mg of Sun Pharmaceutical Industries Ltd, India with Kalydeco (Ivacaftor) 150 mg film-coated tablets, Marketing Authorisation Holder: Vertex Pharmaceuticals (Ireland) Limited Unit 49, Block F2, Northwood Court, Santry, Dublin 9, D09 T665, Ireland, in healthy adult, human subjects under fed condition.Cystic Fibrosis2023-508115-23-00Sun Pharmaceutical Industries Limited52
Recruiting
Not Applicable
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus CompleteConstipationAtopic DermatitisNCT07444008NovoNatum Ltd140